Since current staging systems and biomarkers are limited in their ability to assess risk of recurrence and benefit from adjuvant chemotherapy in early stage lung adenocarcinoma, our mechanistic investigation of TIMP-2 growth-stimulatory activity may represent a tool that could help further refine treatment decisions based on the tumors' molecular profiles. Here, TIMP2 is linked to lung adenocarcinoma.